Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club

Packaging
Return to: PBR Home | Packaging

Novartis to update high blood pressure drug label

PBR Staff Writer Published 22 February 2012

Novartis has planned to update the Rasilez's labelling to include contraindications against combined use with a number of products.

The company will follow the advice of the EMA's Committee for Medicinal Products for Human Use (CHMP) in making changes to the product information details for its high blood pressure therapy.

According to the CHMP, Rasilez and other products containing aliskiren should not be used alongside ACE inhibitors or ARBs in patients with diabetes and/or moderate to severe renal impairment, due to safety concerns.

Novartis Pharmaceuticals division head David Epstein said they are working closely with the CHMP, EMA and other health authorities worldwide to continue to provide Rasilez and combination products containing aliskiren.

 

 

Comments
Post a comment

Comments may be moderated for spam, obscenities or defamation.